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During 1995, Ͼ50 000 cycles of ovarian stimulation for the purposes of in-vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI) or gamete intra-Fallopian transfer (GIFT) were reported in the World Collaborative Report on IVF (1997) and it is believed that equally as many cycles of ovulation induction are undertaken annually. As the overall incidence of clinically relevant ovarian hyperstimulation syndrome (OHSS) occurs in up to 10% of cycles, some of which (0.5-2%) (Forman et al., 1990; Navot et al., 1992) are life-threatening, it is important for clinicians, not only infertility specialists, to be aware of strategies in prevention, diagnosis and treatment. The diagnosis and treatment of OHSS has been extensively reviewed elsewhere (Brinsden et al., 1995) emphasizing the principles of treatment, namely a full clinical examination including weight, an assessment of the degree of hypovolaemia and the presence of any secondary complications such as hypovolaemia, coagulopathy, ascites, hydrothorax, pericardial effusion, oligo-renal failure, ovarian torsion and rupture of ovarian cysts. The treatment of OHSS is directed at providing reassurance, pain relief and supportive therapy to prevent the occurrence of secondary complications and may require outpatient support or, only in the most severe cases, hospitalization, intravenous therapy including reinfusion of ascitic fluid (Aboulghar et al., 1992; Fukaya et al., 1994) , albumin infusions, anticoagulation, paracentesis, pleural tap and, on rare occasions, renal dialysis (Navot et al., 1992) . Typically, recovery, when pregnancy has not occurred, will begin at the end of the luteal phase, being completed by the onset of menstruation. This is not the case when pregnancy has occurred, the time course being some weeks, until presumably the luteotrophic drive from endogenous human chorionic gonadotrophin (HCG) diminishes at 7-10 weeks gestation.
The pathogenesis for OHSS is not well understood, but the major factors seem to be increased capillary permeability and new capillary vessel formation. Oestrogen may be an index of ovarian response but the major mediators of OHSS are thought to be the ovarian renin-angiotensin system (Navot et al., 1992) , prostaglandin synthesis and capillary changes due to substances including serotonin and histamine and vascular endothelial growth factors (Lee et al., 1997) . Two other factors are critical, namely excessive ovarian responsiveness to 'normal doses' of gonadotrophins or clomiphene as seen in women with polycystic ovary syndrome (PCOS) and exogenous or endogenous HCG (Forman et al., 1990) .
Thus strategies for preventing OHSS and its severity have included prediction of women at risk (e.g. diagnosis of PCOS), administration of a gonadotrophin dosage according to a woman's age, weight and follicular phase follicle stimulating hormone (FSH) concentrations, cancellation of a treatment cycle when the serum oestradiol concentration is grossly elevated (ജ10 000 pmol/l) or ജ20 follicles are seen ultrasonically, proceeding to oocyte retrieval with meticulous aspiration of all follicles at oocyte retrieval (Hazout et al., 1984) , cryopreservation of all embryos (Wada et al., 1993) , reducing the dose of HCG trigger (Abdalla et al., 1983) , withholding the HCG trigger and postponing the treatment cycle until the ovaries have been rendered quiescent by prolonged use of gonadotrophin releasing hormone (GnRH) agonists and ovarian stimulation started again at a lower dosage (Forman et al., 1990) . Limiting the amounts of gonadotrophins in the 'low dose' protocol with or without minimal clomiphene citrate or even no gonadotrophins (Dickey and Holtkamp, 1996; Edwards et al., 1996; ESHRE Capri Workshop, 1997; Kousta et al., 1997) could be utilized in the variants with excessive ovarian responsiveness to 'normal doses' of gonadotrophins. Intravenous albumin has also been used intra-operatively at the time of oocyte retrieval in an attempt to reduce the incidence or severity of OHSS (Asch et al., 1993; Ng et al., 1995) . The choice of strategy adopted is dependent on the woman's clinical status, compliance and wishes, the facilities available to closely monitor events (daily oestradiol assays and scans) and to provide embryo cryopreservation and emergency care. Typically, embryo transfer is inadvisable if serum oestradiol is ജ10 000 pmol/l or if symptoms of OHSS are present.
Little has been seen until recently in peer-reviewed literature of strategies referred to as 'coasting', i.e. continuation of GnRH agonists for a few to several days (Sher et al., 1995; Benadiva et al., 1997) , early follicle aspiration timed at 10-12 h after HCG trigger administration (Tomazevic and MedenVrtovec, 1996) , ovarian diathermy or laser vaporization (Fukaya et al., 1995; Rimington et al., 1997; Egbase et al., 1998) immediately prior to the commencement of ovarian stimulation in women deemed to be at risk of OHSS. A series of abstracts and publications this year are likely to renew active interest in these strategies.
Laparoscopic ovarian diathermy has largely replaced bilateral ovarian wedge resection in women with clomiphene resistant PCOS, the return to spontaneous ovulation being seen in 60-70% of women soon after surgery. The use of this technique to prevent OHSS in women at risk has been reported, diathermy being performed in either one (Egbase et al., 1998) or both (Rimington et al., 1997) ovaries. The mechanism of the effect is not clear but it is likely to be due simply to reduction in functioning ovarian mass. Concern has been expressed about the complications of these techniques, not only the risk of adhesion formation (Saravelos and Li, 1996) but also concern about ovarian atrophy due to devascularization. Egbase and colleagues (1998) described IVF treatment using equivalent doses of human menopausal gonadotrophin (HMG) in the repeated IVF cycles of three women who had been hospitalized with severe OHSS following the first treatment cycle, unilateral ovarian diathermy having been performed 4-6 weeks prior to commencement of the second cycle. Rimington et al. (1997) reported a randomized study of the successful treatment of 25 women considered to be at risk of OHSS who had bilateral ovarian diathermy whilst undergoing pituitary desensitization just prior to HMG administration for ovarian stimulation. Tomazevic and Meden-Vrtovec (1996) in their observational study described the value of reducing the incidence of OHSS using early timed follicular aspiration (ETFA) of one ovary 10-12 h after the administration of HCG in 106 women in comparison to 92 women with similar risk features who acted as controls. There were no cases of severe OHSS in the women who underwent ETFA in comparison with 16 women with severe OHSS in the control group. The live birth rate (16%) was comparable in both groups. We have evaluated the use of ETFA 6-8 h prior to the time of HCG administration in a randomized study of 16 women (Egbase et al., 1997) . As we did not observe any differences in the incidence or severity of OHSS in these women, we concluded that the timing of ETFA is likely to be a critical factor in this strategy.
A novel approach proposed by Sher et al. (1995) appears to be the focus of renewed interest, namely withholding gonadotrophins whilst continuing desensitization with GnRH agonist in women with high serum oestradiol concentrations (ജ6000 pg/ml) and Ͼ20 follicles in each ovary, and delaying the HCG trigger injection until the serum oestradiol concentration has fallen to Ͻ3000 pg/ml. The gonadotrophin-free intervals described have varied between 2 and 8 days, all but one study (Shapiro et al., 1997) reporting a substantial reduction in the occurrence of severe OHSS without a fall in clinical pregnancy or live birth rates (Sher et al., 1993; Benadiva et al., 1997; Tortoriello et al., 1997; Van der Stracten et al., 1997; U.Waldenstrom, personal communication) . The notable features of this strategy have been firstly an apparent reduction of severe OHSS and secondly the new observation that withholding gonadotrophins for up to several days leads to a reduction in the number of oocytes harvested without an apparent deterioration in the function of the oocyte in terms of rates of fertilization, embryonic development and clinical pregnancy. How this approach works is unclear but falling serum oestradiol concentrations would appear to reflect substantial changes in some of the follicles but not all. It is of more than passing interest that Meden-Vrtovec and Tomazevic (1995) described a fall in circulating oestradiol concentrations following ETFA (Meden-Vrtovec and Tomazevic, 1995) . Whereas Benadiva et al. (1997) reported a modest reduction in incidence of severe OHSS in their retrospective studies, the duration of withholding gonadotrophins was short, the mean 2052 being 1.9 Ϯ 0.9 days. It seems that withholding gonadotrophins for longer does affect ovarian function in some respects but not individual oocyte function in general, permitting normal fertilization and embryonic development leading to apparently normal pregnancy outcome. Randomized prospective controlled studies varying the duration of withholding gonadotrophins will determine the optimal interval, as well as the effects on ovarian or oocyte function, which will permit satisfactory pregnancy rates in these women without exposing them to the complications of severe OHSS.
